SCYNEXIS, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SCYX Nasdaq 2830 www.scynexis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SCYNEXIS, Inc.

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases - Oct 22nd, 2026 6:00 am
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek - Oct 21st, 2026 2:05 pm
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Oct 6th, 2026 5:30 am
Scynexis stock surges on $214M BARDA contract for SCY-247 - Sep 28th, 2026 7:58 am
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract - Sep 28th, 2026 6:10 am
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 - Sep 28th, 2026 5:30 am
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - Sep 22nd, 2026 6:00 am
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - Sep 15th, 2026 6:00 am
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer - Sep 10th, 2026 6:00 am
SCYNEXIS to Participate in Upcoming Investor Conferences - Sep 1st, 2026 6:30 am
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Aug 25th, 2026 5:06 pm
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 10th, 2026 2:30 pm
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Jun 30th, 2026 6:00 am
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested - Jun 1st, 2026 12:14 am
SCYNEXIS Announces One-for-Eight Reverse Stock Split - May 22nd, 2026 2:15 pm
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 11th, 2026 2:23 pm
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 6th, 2026 7:15 pm
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease - Mar 31st, 2026 5:59 am
SCYNEXIS Announces $40.0 Million Private Placement - Mar 31st, 2026 4:45 am
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mar 31st, 2026 4:40 am